P. Lønning

发表

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

R. Tibshirani, T. Hastie, D. Botstein, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Repeated observation of breast tumor subtypes in independent gene expression data sets

R. Tibshirani, T. Hastie, A. Nobel, 2003, Proceedings of the National Academy of Sciences of the United States of America.

implications Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical

R. Tibshirani, D. Botstein, P. Brown, 2001 .

Genetic variants of CYP19 (aromatase) and breast cancer risk

P. Lønning, A. Børresen-Dale, V. Kristensen, 2000, Oncogene.

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens

P. Lønning, S. Knappskog, I. Løes, 2014, Tumor Biology.

Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays

Ash A. Alizadeh, Christian A. Rees, D. Botstein, 1999, Nature Genetics.

Breast cancer prognostication and prediction in the postgenomic era.

P. Lønning, S. Knappskog, J. Lillehaug, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors

Christian A. Rees, R. Tibshirani, D. Botstein, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Genetic variation in putative regulatory loci controlling gene expression in breast cancer

A. Tsalenko, R. Sharan, Z. Yakhini, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel

T. Aas, P. Lønning, A. Nysted, 2011, PloS one.

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

Steinar Lundgren, Stian Knappskog, Lars Fredrik Engebretsen, 2008, PloS one.

TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.

Jürgen Geisler, Per Eystein Lønning, T. Aas, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

T. Aas, S. Geisler, H. Johnsen, 2001, Cancer research.

Influence of TP 53 Gene Alterations and c-erbB2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer 1

Dagny Faksvåg Haugen, Per Eystein Lønning, T. Aas, 2001 .

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

T. Aas, S. Geisler, H. Johnsen, 1996, Nature Medicine.

P53 and its molecular basis to chemoresistance in breast cancer

P. Lønning, S. Knappskog, 2012, Expert opinion on therapeutic targets.

Intratumoral Estrogen Disposition in Breast Cancer

P. Lønning, M. Dowsett, J. Geisler, 2010, Clinical Cancer Research.

Performance of two prognostic scores that incorporate genetic information to predict long‐term outcomes following resection of colorectal cancer liver metastases: An external validation of the MD Anderson and JHH‐MSK scores

P. Lønning, I. Endo, P. Kornprat, 2021, Journal of hepato-biliary-pancreatic sciences.

Subclonal diversification of primary breast cancer revealed by multiregion sequencing

Andrew Menzies, Keiran Raine, Young Seok Ju, 2015, Nature Medicine.

Breast cancer prognostication and prediction: are we making progress?

P. Lønning, P E Lønning, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Genomics-based prognosis and therapeutic prediction in breast cancer.

S. Jeffrey, P. Lønning, B. Hillner, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Genomics in breast cancer—therapeutic implications

T. Sørlie, P. Lønning, A. Børresen-Dale, 2005, Nature Clinical Practice Oncology.

Kinetics of plasma total homocysteine in patients receiving high-dose methotrexate therapy.

P. Lønning, P. Ueland, A. Guttormsen, 1998, Clinical chemistry.

Genomic Evolution of Breast Cancer Metastasis and Relapse

P. Lønning, M. Stratton, P. Campbell, 2017, Cancer cell.

Predicting long‐term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

P. Lønning, T. Bathen, B. Sitter, 2012, NMR in biomedicine.

Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer

A. Nobel, D. Botstein, C. Fan, 2006, Molecular Cancer Therapeutics.

Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome

M. Ringnér, P. Lønning, Å. Borg, 2010, Clinical Cancer Research.

Mutation of GATA3 in human breast tumors

R. Strausberg, C. Perou, P. Lønning, 2004, Oncogene.

Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease.

P. Lønning, P. Ueland, A. Svardal, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Endocrine Treatment – ‘Old-Fashioned’ Therapy Becoming Redundant in an Era of Molecular Medicine?

P. Lønning, 2008, Breast Care.

Aromatase inhibitors in the treatment of early and advanced breast cancer

P. Lønning, H. Joensuu, L. Rutqvist, 2005, Acta oncologica.

Role of endocrine therapy in breast cancer—where are we going?

P. Lønning, 2004 .

Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators

P. Lønning, 2003, Clinical pharmacokinetics.

Clinical trials in breast cancer; do we have the right approaches?

P. Lønning, 2000, Breast Cancer Research.

Exemestane in breast cancer: current status and future directions.

P. Lønning, 2000, Clinical breast cancer.

Pharmacology and clinical experience with exemestane

P. Lønning, 2000, Expert opinion on investigational drugs.

Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.

P. Lønning, G. Anker, P. Ueland, 1999, Clinical chemistry.

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

P. Lønning, P. Goss, J. Bartlett, 2008, The oncologist.

cancer clinical treatment response in locally advanced breast Gene expression profiles do not consistently predict the

A. Nobel, D. Botstein, C. Fan, 2011 .

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.

P. Lønning, M. Cheang, V. Speirs, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Hospital volume and prognosis among Norwegian breast cancer patients enrolled in adjuvant trials

P. Lønning, H. E. Fjösne, S. Lundgren, 2011, Acta oncologica.

Additive endocrine therapy for advanced breast cancer – back to the future

P. Lønning, 2009, Acta oncologica.

ramr: an R package for detection of rare aberrantly methylated regions

P. Lønning, S. Knappskog, O. Nikolaienko, 2020, bioRxiv.

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

P. Lønning, 2009, European journal of cancer.

Long-Term Follow-Up of the Intergroup Exemestane Study.

P. Lønning, L. Fallowfield, R. Paridaens, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.

P. Lønning, M. Dowsett, N. Davidson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P. Lønning, J. Forbes, R. Paridaens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Indications and limitations of third-generation aromatase inhibitors

P. Lønning, J. Geisler, 2008, Expert opinion on investigational drugs.

Adjuvant endocrine treatment of early breast cancer.

P. Lønning, 2007, Hematology/Oncology Clinics of North America.

The potential for aromatase inhibition in breast cancer prevention.

P. Lønning, B. Erikstein, J. Geisler, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer

P. Lønning, S. Knappskog, A. H. Straume, 2019, bioRxiv.

Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer

P. Lønning, H. Adlercreutz, S. Helle, 2005, Breast Cancer Research and Treatment.

Adeno‐associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma

P. Lønning, R. Kotin, R. Bjerkvig, 2006, The journal of gene medicine.

Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts.

P. Lønning, R. Kotin, R. Bjerkvig, 2005, Human gene therapy.

Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres

P. Lønning, R. Bjerkvig, M. Wold, 2007, Nucleic acids research.

Interpreting plasma estrogen levels in breast cancer: caution needed.

P. Lønning, M. Dowsett, E. Folkerd, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples

P. Lønning, J. Geisler, Hildegunn Helle, 2008, The Journal of Steroid Biochemistry and Molecular Biology.

Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels

P. Lønning, M. Dowsett, J. Geisler, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

Comparison between aromatase inhibitors and sequential use

P. Lønning, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Expert Opinion on Investigational Drugs

P. Lønning, 2000 .

An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range

P. Lønning, R. Kellmann, K. Viste, 2020, Journal of the Endocrine Society.

Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

P. Lønning, T. Decker, A. Leo, 2017 .

Oestrogen suppression--lessons from clinical studies.

P. Lønning, 2004, Best practice & research. Clinical endocrinology & metabolism.

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

P. Lønning, A. Howell, G. Anker, 2001, Breast Cancer Research and Treatment.

Development of Aromatase Inhibitors and Their Pharmacologic Profile

P. Lønning, J. Geisler, A. Bhatnager, 2003, American journal of clinical oncology.

Aromatase inhibitors and inactivators for breast cancer treatment.

P. Lønning, 2002, European Journal of Cancer.

The role of aromatase inactivators in the treatment of breast cancer

P. Lønning, P. Lønning, 2002, International Journal of Clinical Oncology.

Stepwise estrogen suppression manipulating the estrostat

P. Lønning, 2001, The Journal of Steroid Biochemistry and Molecular Biology.

Aromatase inhibitors and inactivators in breast cancer

P. Lønning, 2001, BMJ : British Medical Journal.

Exemestane: a review of its clinical efficacy and safety.

P. Lønning, 2001, Breast.

Clinico-pharmacological aspects of different hormone treatments.

P. Lønning, 2000, European journal of cancer.

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.

P. Lønning, N. Aaronson, M. Tubiana-Hulin, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.

P. Lønning, M. Dowsett, S. Lundgren, 1996, British Journal of Cancer.

Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.

P. Lønning, S. Lundgren, S. Helle, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Patterns of genomic evolution in advanced melanoma

P. Lønning, E. Hovig, O. Myklebost, 2018, Nature Communications.

Plasma changes in breast cancer patients during endocrine therapy — lipid measurements and nuclear magnetic resonance (NMR) spectroscopy

P. Lønning, J. Krane, D. Johannessen, 2004, Breast Cancer Research and Treatment.

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum

P. Lønning, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations

P. Lønning, J. Geisler, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Ineffective Inhibition of Aromatase: A Cause for AI Resistance?

P. Lønning, 2015 .

Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status

T. Aas, P. Lønning, J. Geisler, 2009, The Journal of Steroid Biochemistry and Molecular Biology.

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

P. Lønning, B. Naume, E. Schlichting, 2018, Breast Cancer Research.

Bone safety of aromatase inhibitors versus tamoxifen.

P. Lønning, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

P. Lønning, J. Geisler, G. Eide, 2006, European journal of cancer.

Pharmacology of new aromatase inhibitors

P. Lønning, 1996 .

Dose Response Evaluation

P. Lønning, 1993, Clinical pharmacokinetics.

DNA Methylation Status of Key Cell-Cycle Regulators Such as CDKNA2/p16 and CCNA1 Correlates with Treatment Response to Doxorubicin and 5-Fluorouracil in Locally Advanced Breast Tumors

P. Lønning, A. Børresen-Dale, V. Kristensen, 2014, Clinical Cancer Research.

Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series.

P. Lønning, I. Løes, elliot k fishman, 2018, Anticancer research.

Molecular portraits of human breast tumours

Christian A. Rees, D. Botstein, P. Brown, 2000, Nature.

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.

P. Lønning, T. Powles, M. Dowsett, 1992, British Journal of Cancer.

DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival

P. Lønning, T. Bathen, S. Knappskog, 2022, Breast Cancer Research.

Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.

T. Aas, P. Lønning, S. Lundgren, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

P. Lønning, S. Johnston, T. Decker, 2018, The Lancet. Oncology.

Adjuvant treatment: the contribution of expression microarrays

P. Lønning, S. Knappskog, J. Lillehaug, 2007, Breast Cancer Research.

Genetic and Epigenetic Changes in p21 and p21B Do Not Correlate with Resistance to Doxorubicin or Mitomycin and 5-Fluorouracil in Locally Advanced Breast Cancer

P. Lønning, J. Lillehaug, V. Staalesen, 2004, Clinical Cancer Research.

Genetic and Epigenetic Changes in p 21 and p 21 B Do Not Correlate with Resistance to Doxorubicin or Mitomycin and 5-Fluorouracil in Locally Advanced Breast Cancer

P. Lønning, J. Lillehaug, V. Staalesen, 2004 .

DNA methylation subgroups in melanoma are associated with proliferative and immunological processes

M. Ringnér, P. Lønning, M. Lauss, 2015, BMC Medical Genomics.

Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer

C. Perou, T. Sørlie, P. Lønning, 2004, Cancer Research.

Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation.

P. Lønning, H. Immervoll, R. Bjerkvig, 2009, Cancer research.

Human endotrophin as a driver of malignant tumor growth.

P. Lønning, P. Scherer, Jiyoung Park, 2019, JCI insight.

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.

P. Lønning, T. Powles, M. Dowsett, 1991, British Journal of Cancer.

Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

P. Lønning, J. Paolini, D. Johannessen, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients.

P. Lønning, J. Cameron, T. Pawlik, 2018, Annals of surgery.

Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin‐like growth factors and IGF binding proteins 1 and 3: a cross‐over study

P. Lønning, J. Holly, S. Helle, 1996, Clinical endocrinology.

ABCB1 and GST polymorphisms associated with TP53 status in breast cancer

Marylyn D. Ritchie, Vessela N. Kristensen, Marianne Berg, 2007, Pharmacogenetics and genomics.

Pathway based analysis of SNPs with relevance to 5‐FU therapy: Relation to intratumoral mRNA expression and survival

A. Tsalenko, T. Sørlie, P. Lønning, 2008, International journal of cancer.

The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids

P. Lønning, J. Holly, S. Helle, 2002, The Journal of Steroid Biochemistry and Molecular Biology.

Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer

P. Lønning, L. Vatten, P. Romundstad, 2021, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk

P. Lønning, L. Vatten, P. Romundstad, 2017, BMC Cancer.

Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking.

P. Lønning, J. Geisler, S. Helle, 1999, The Journal of endocrinology.

Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer

P. Lønning, O. Bakke, S. Kvinnsland, 1984, Clinical pharmacology and therapeutics.

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells

P. Lønning, S. Knappskog, B. Mannsăker, 2017, BMC Cell Biology.

MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk

P. Lønning, L. Vatten, P. Romundstad, 2012, PloS one.

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.

P. Lønning, L. Vatten, P. Romundstad, 2012, European journal of cancer.

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

P. Lønning, S. Knappskog, 2011, Transcription.

Estradiol measurement in translational studies of breast cancer

P. Lønning, 2015, Steroids.

Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.

P. Lønning, M. Dowsett, B. Haynes, 2014, European journal of cancer.

Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding?

P. Lønning, J. Geisler, 2010, The Journal of Steroid Biochemistry and Molecular Biology.

Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?

P. Lønning, 2008, Anti-cancer drugs.

Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels

T. Aas, P. Lønning, J. Geisler, 2008, Clinical Cancer Research.

Clinical pharmacology of aromatase inhibitors

P. Lønning, J. Geisler, 2008 .

Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression

P. Lønning, J. Geisler, 2008, The Journal of Steroid Biochemistry and Molecular Biology.

Pharmacological and clinical profile of anastrozole

P. Lønning, M. Dowsett, J. Geisler, 2004, Breast Cancer Research and Treatment.

The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients

P. Lønning, T. Powles, M. Dowsett, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of third-generation aromatase inhibitors.

P. Lønning, C. Zamagni, A. Martoni, 2003, Seminars in oncology.

Overview of Aromatase Inhibitors and Inactivators in the Treatment of Advanced Breast Cancer

P. Lønning, 2002 .

Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate

P. Lønning, J. Geisler, D. Johannessen, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients

P. Lønning, J. Geisler, E. Lien, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.

P. Lønning, J. Geisler, G. Anker, 1996, European journal of cancer.

A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors

P. Lønning, D. Ekse, 1995, The Journal of Steroid Biochemistry and Molecular Biology.

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.

P. Lønning, T. Powles, M. Dowsett, 1994, British Journal of Cancer.

Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.

P. Lønning, H. Adlercreutz, T. Fotsis, 1993, British Journal of Cancer.

Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition.

P. Lønning, T. Thorsen, D. Johannessen, 1989, Journal of steroid biochemistry.

Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide.

P. Lønning, P. Skulstad, Per Skulstad, 1989, Journal of steroid biochemistry.

Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo.

P. Lønning, M. Dowsett, B. Haynes, 1991, Journal of enzyme inhibition.

Alterations in the Metabolism of Oestrogens During Treatment with Aminoglutethimide in Breast Cancer Patients

T. Thorsen, P. Lønning, P. Ueland, 1987, Clinical pharmacokinetics.

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.

P. Lønning, T. Powles, M. Dowsett, 1992, European journal of cancer.

Mutations and polymorphisms of the p21B transcript in breast cancer

P. Lønning, A. Børresen-Dale, I. Gram, 2007, International journal of cancer.

Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer

P. Lønning, A. Buzdar, M. Lichinitser, 2002, Breast Cancer Research and Treatment.

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy

T. Aas, S. Geisler, P. Lønning, 2022, Genome medicine.

A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue

P. Lønning, J. Geisler, H. Berntsen, 2000, The Journal of Steroid Biochemistry and Molecular Biology.

Hormonal therapies of metastatic breast cancer: the past and the present

P. Lønning, J. Geisler, 2007 .

HORMONAL THERAPIES OF METASTATIC

P. Lønning, J. Geisler, 2007 .

Aromatase Inhibitors in Malignant Diseases of Aging

P. Lønning, D. Johannessen, 1992, Drugs & aging.

The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling

P. Lønning, T. Flatmark, R. Bjerkvig, 2008, Oncogene.

Vitamin D deficiency: A threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors.

P. Lønning, J. Geisler, G. Eide, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Megestrol acetate versus aminoglutethimide for metastatic breast cancer

P. Lønning, S. Lundgren, S. Gundersen, 1989, Breast Cancer Research and Treatment.

Alterations in the insulin-like growth factor system during the menstrual cycle in normal women.

P. Lønning, G. Anker, J. Holly, 1998, Maturitas.

Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique

P. Lønning, J. Aarseth, S. E. Monstad, 2006, Cancer Immunology, Immunotherapy.

The TP 53 Codon 72 Polymorphism May Affect the Function of TP 53 Mutations in Breast Carcinomas but not in Colorectal Carcinomas 1

P. Lønning, A. Børresen-Dale, R. Lothe, 2002 .

Session 6 introduction

P. Lønning, J. F. Robertson, 2010, Breast Cancer Research.

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer

Robert Tibshirani, Therese Sørlie, R. Tibshirani, 2006, Genes, chromosomes & cancer.

Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.

P. Lønning, M. Dowsett, D. Hayes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemosensitivity and p53; new tricks by an old dog

P. Lønning, S. Knappskog, 2012, Breast Cancer Research.

Lipid and coagulation profile in postmenopausal women with early breast cancer at low risk treated with exemestane: A randomized, placebo-controlled study.

P. Lønning, L. Ottestad, J. Geisler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk.

P. Lønning, L. Ottestad, J. Geisler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutant KRAS as a prognostic biomarker after hepatectomy for rectal cancer metastases: Does the primary disease site matter?

P. Lønning, I. Endo, P. Kornprat, 2021, Journal of hepato-biliary-pancreatic sciences.

Lack of Diurnal-Variation in Plasma-Levels of Androstenedione, Testosterone, Estrone and Estradiol in Postmenopausal Women

P. Lønning, T. Powles, M. Dowsett, 1989 .

Aromatase activity, serum oestradiol and their correlation with demographic indices

P. Lønning, T. Powles, M. Dowsett, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

Multilocus analysis of SNP and metabolic data within a given pathway

A. Tsalenko, Z. Yakhini, P. Lønning, 2006, BMC Genomics.

Impact of aromatase inhibitors on bone health in breast cancer patients

P. Lønning, J. Geisler, 2010, The Journal of Steroid Biochemistry and Molecular Biology.

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells

P. Lønning, S. Knappskog, B. Mannsăker, 2017, Translational oncology.

Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment

P. Lønning, T. Powles, M. Dowsett, 2005, Breast Cancer Research and Treatment.

Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer

P. Lønning, 2004, Breast Cancer Research and Treatment.

Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer

P. Lønning, T. Powles, M. Dowsett, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and metabolism of formestane in breast cancer patients

P. Lønning, J. Geisler, W. Miller, 2001, The Journal of Steroid Biochemistry and Molecular Biology.

Exemestane experience in breast cancer treatment

P. Lønning, R. Paridaens, B. Thürlimann, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

New endocrine drugs for treatment of advanced breast cancer.

P. Lønning, 1990, Acta oncologica.

Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA

P. Lønning, R. Bjerkvig, A. Jul-Larsen, 2006, Journal of Cell Science.

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

T. Aas, P. Lønning, S. Knappskog, 2014, Acta oncologica.

Using Artificial Intelligence to Find the Optimal Margin Width in Hepatectomy for Colorectal Cancer Liver Metastases.

D. Bertsimas, P. Lønning, T. Pawlik, 2022, JAMA Surgery.

Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen

P. Lønning, G. Anker, P. Ueland, 2006, International journal of cancer.

Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors.

P. Lønning, R. Bjerkvig, F. Thorsen, 2002, Human gene therapy.

Insulin-like growth factors in breast and prostatic cancer

P. Lønning, S. Helle, 1995 .

RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.

P. Lønning, S. Knappskog, C. Busch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Aromatase inhibition for breast cancer treatment.

P. Lønning, 1996, Acta oncologica.

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer

P. Lønning, R. Prentice, S. Knappskog, 2022, JAMA oncology.

Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer.

P. Lønning, J. Holly, J. Holly, 1996, The Journal of clinical endocrinology and metabolism.

Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients

P. Lønning, D. Johannessen, A. Aakvaag, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

Genomic heterogeneity in primary breast cancer: Clinical implications.

P. Lønning, M. Stratton, P. Campbell, 2014 .

The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy.

P. Lønning, S. Frøland, T. Ueland, 2001, The Journal of clinical endocrinology and metabolism.

Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer?

P. Lønning, J. Geisler, 2006, Nature Clinical Practice Oncology.

Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique

P. Lønning, J. Aarseth, S. E. Monstad, 2006, Clinical and experimental immunology.

Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer

P. Lønning, J. Geisler, G. Anker, 2001, British Journal of Cancer.

Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research.

P. Lønning, J. Klijn, R. Paridaens, 1994, European journal of cancer.

Single-Dose and Steady-State Pharmacokinetics of Aminoglutethimide

P. Lønning, P. Ueland, S. Kvinnsland, 1985, Clinical pharmacokinetics.

Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.

P. Lønning, G. Anker, P. Ueland, 1990, Cancer research.

Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine.

P. Lønning, G. Anker, P. Ueland, 1997, Biochemical Society Transactions.

Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients

P. Lønning, M. Dowsett, J. Geisler, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Effect of methotrexate on homocysteine and other sulfur compounds in tissues of rats fed a normal or a defined, choline-deficient diet

P. Lønning, P. Ueland, A. Svardal, 2004, Cancer Chemotherapy and Pharmacology.

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

P. Lønning, L. Fallowfield, L. Gibson, 2004, The New England journal of medicine.

APOBEC3A/B deletion polymorphism and endometrial cancer risk

P. Lønning, L. Vatten, P. Romundstad, 2022, Cancer medicine.

Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women.

P. Lønning, T. Powles, M. Dowsett, 1990, Journal of steroid biochemistry.

Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment.

P. Lønning, S. Gundersen, N. Raabe, 1998, Acta oncologica.

epialleleR: an R/BioC package for sensitive allele-specific methylation analysis in NGS data

P. Lønning, S. Knappskog, O. Nikolaienko, 2022 .

Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status

T. Aas, P. Lønning, J. Geisler, 2010, The Journal of Steroid Biochemistry and Molecular Biology.

Aminoglutethimide enzyme induction: pharmacological and endocrinological implications

P. Lønning, 2008, Cancer Chemotherapy and Pharmacology.

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

P. Lønning, S. Knappskog, D. Solit, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy

T. Aas, S. Geisler, P. Lønning, 2022, Genome medicine.

MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells1

P. Lønning, Ping Chen, A. H. Straume, 2018, Translational oncology.

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.

P. Lønning, M. Dowsett, J. Geisler, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter.

R. Bjerkvig, P. Lønning, S. Knappskog, 2010, Cancer research.

Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer

T. Sørlie, T. Aas, S. Geisler, 2011, British Journal of Cancer.

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved

P. Lønning, H. P. Eikesdal, 2013, Endocrine-related cancer.

Treatment of early breast cancer with conservation of the breast. A review.

P. Lønning, 1991, Acta oncologica.

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.

M. Ringnér, P. Lønning, Å. Borg, 2015, The Journal of investigative dermatology.

Thyroid function in postmenopausal breast cancer patients treated with tamoxifen.

P. Lønning, G. Anker, A. Aakvaag, 1998, Scandinavian journal of clinical and laboratory investigation.

Golgi-Localized PAQR4 Mediates Antiapoptotic Ceramidase Activity in Breast Cancer

P. Lønning, S. Knappskog, A. Molven, 2020, Cancer Research.

Golgi-localized PAQR4 mediates Anti-apoptotic Ceramidase Activity in Breast Cancer

P. Lønning, S. Knappskog, A. Molven, 2019, bioRxiv.

Differential effect of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients.

S. Geisler, P. Lønning, J. Geisler, 1997, The Journal of endocrinology.

The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.

P. Lønning, A. Børresen-Dale, R. Lothe, 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer

P. Lønning, S. Lundgren, A. Aakvaag, 2004, Cancer Chemotherapy and Pharmacology.

Clinical Pharmacokinetics of Endocrine Agents Used in Advanced Breast Cancer

P. Lønning, S. Lundgren, E. Lien, 1992, Clinical pharmacokinetics.

Gene Mutations Predict the Response to Neoadjuvant Treatment with 5-Fluorouracil and Mitomycin in Locally Advanced Breast Cancer

T. Aas, S. Geisler, H. Johnsen, 2003 .

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines

P. Lønning, S. Knappskog, H. P. Eikesdal, 2017, Oncotarget.

Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues.

P. Lønning, T. Christoffersen, T. Guren, 2009, European journal of pharmacology.

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

P. Lønning, S. Knappskog, P. Lønning, 2013, Oncogene.

Molecular basis for therapy resistance

P. Lønning, 2010, Molecular oncology.

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

P. Lønning, B. Naume, E. Schlichting, 2018, Breast Cancer Research.

CHEK 2 Mutations Affecting Kinase Activity Together With Mutations in TP 53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

P. Lønning, S. Lundgren, S. Knappskog, 2009 .

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

P. Lønning, S. Knappskog, 2011, Oncotarget.

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

P. Lønning, P. Romundstad, S. Knappskog, 2021, Scientific Reports.

APOBEC3A/B deletion polymorphism and cancer risk

P. Lønning, L. Vatten, S. Nik-Zainal, 2017, Carcinogenesis.

Constitutional Mosaic Epimutations - a hidden cause of cancer?

P. Lønning, S. Knappskog, I. Løes, 2019, Cell stress.

The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy

P. Lønning, H. P. Eikesdal, Eilin Austreid, 2014, Expert opinion on pharmacotherapy.

Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters

S. Geisler, P. Lønning, A. Børresen-Dale, 2006, Molecular Cancer.

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

P. Lønning, H. Ditzel, T. Tan, 2019, Cancer & Metabolism.

Alternative splicing and mutation status of CHEK2 in stage III breast cancer

S. Geisler, P. Lønning, A. Børresen-Dale, 2004, Oncogene.

Microarrays in primary breast cancer--lessons from chemotherapy studies.

D. Botstein, C. Perou, T. Sørlie, 2001, Endocrine-related cancer.

Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival

P. Lønning, J. Nesland, S. Lundgren, 2012, Breast Cancer Research.

MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.

P. Lønning, J. Geisler, C. Busch, 2010, European journal of cancer.

Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors

P. Lønning, A. Børresen-Dale, V. Kristensen, 2013, BMC Cancer.

Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells’ sensitivity to paclitaxel

P. Lønning, S. Hautaniemi, Ping Chen, 2016, Oncotarget.

Divergent Activity of the Pseudogene PTENP1 in ER-Positive and Negative Breast Cancer

P. Lønning, K. Skaftnesmo, H. P. Eikesdal, 2017, Molecular Cancer Research.

Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines

P. Lønning, S. Knappskog, Johanna Huun, 2017, Cell Death Discovery.

Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649)

P. Lønning, D. Charlesworth, L. Aaltonen, 2014, Oncotarget.

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate

P. Lønning, L. Vatten, P. Romundstad, 2016, Oncotarget.

The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer

P. Lønning, L. Vatten, P. Romundstad, 2016, Tumor Biology.

MDM4 SNP34091 (rs4245739) and its effect on breast‐, colon‐, lung‐, and prostate cancer risk

P. Lønning, L. Vatten, P. Romundstad, 2015, Cancer medicine.

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers

P. Lønning, S. Knappskog, A. Dørum, 2012, BMC Cancer.

GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas.

Z. Yakhini, P. Lønning, A. Børresen-Dale, 2008, Cancer research.

DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival

Sampsa Hautaniemi, Marko Laakso, Riku Louhimo, 2016, Oncotarget.

Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection

P. Lønning, R. Lothe, S. Knappskog, 2016, PLoS genetics.

C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer

P. Lønning, S. Knappskog, A. Molven, 2020, bioRxiv.

Molecular classes of breast cancer and their clinical relevance

P. Lønning, 2009 .

Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity.

P. Lønning, J. Lillehaug, V. Staalesen, 2010, Biochimica et biophysica acta.

Aromatase Inhibitors and Inactivators for Breast Cancer Therapy

P. Lønning, 2002, Drugs & aging.

Antitumor efficacy improved by local delivery of species-specific endostatin.

T. B. Pedersen, P. Lønning, O. Haraldseth, 2006, Journal of neurosurgery.

Distinct Patterns of DNACopy Number Alteration Are Associated with Different Clinicopathological Features and Gene-Expression Subtypes of Breast Cancer

R. Tibshirani, T. Sørlie, P. Lønning, 2009 .

Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast Cancer

P. Lønning, S. Kvinnsland, 1988, Drugs.

Separation of urinary metabolites of radiolabelled estrogens in man by HPLC.

P. Lønning, T. Thorsen, A. Sunde, 1989, Journal of steroid biochemistry.

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.

P. Lønning, T. Powles, M. Dowsett, 1991, British Journal of Cancer.

Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.

P. Lønning, T. Powles, M. Dowsett, 1990, Journal of steroid biochemistry.

Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.

P. Lønning, R. Klepp, S. Kvinnsland, 1990, Acta oncologica.

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue

P. Lønning, S. Knappskog, G. Mellgren, 2013, PloS one.

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors

P. Lønning, J. Geisler, G. Mellgren, 2009, British Journal of Cancer.

CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.

P. Lønning, A. Børresen-Dale, V. Kristensen, 1999, Cancer research.

Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo

T. Aas, S. Geisler, P. Lønning, 2015, Molecular oncology.

The multitude of molecular analyses in cancer: the opening of Pandora’s box

P. Lønning, A. Børresen-Dale, H. Russnes, 2014, Genome Biology.

Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer

P. Lønning, Yuhree Kim, J. Cameron, 2018, JAMA surgery.

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases

P. Lønning, S. Knappskog, H. Sorbye, 2016, International journal of cancer.

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.

T. Aas, S. Geisler, T. Thorsen, 2003, European journal of cancer.

Vascular proliferation is a prognostic factor in breast cancer

P. Lønning, W. Foulkes, L. Akslen, 2012, Breast Cancer Research and Treatment.

Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy.

P. Lønning, E. Lien, 2000, Cancer treatment reviews.

Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.

T. Aas, S. Geisler, P. Lønning, 1997, British Journal of Cancer.

The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.

Dongxin Lin, Peter Devilee, Caroline Seynaeve, 2011, Cancer cell.

Paclitaxel and Docetaxel

P. Lønning, 1995, PharmacoEconomics.

Study of suboptimum treatment response: lessons from breast cancer.

P. Lønning, 2003, The Lancet. Oncology.

High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function

P. Lønning, S. Knappskog, R. Chrisanthar, 2017, Breast Cancer Research and Treatment.

Assessment of tumor suppressor promoter methylation in healthy individuals

P. Lønning, S. Knappskog, Eivind Valen, 2020, Clinical epigenetics.

Haplotypes associated to gene expression in breast cancer: can they lead us to the susceptibility markers?

A. Tsalenko, A. Frigessi, Z. Yakhini, 2018, bioRxiv.

Prevalence of the CHEK2 R95* germline mutation

P. Lønning, L. Vatten, P. Romundstad, 2016, Hereditary Cancer in Clinical Practice.

Aromatase inhibitors in breast cancer.

P. Lønning, 2004, Endocrine-related cancer.

Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients

P. Lønning, G. Anker, M. Tally, 1996, The Journal of Steroid Biochemistry and Molecular Biology.

Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients

P. Lønning, J. Geisler, D. Ekse, 1995, The Journal of Steroid Biochemistry and Molecular Biology.

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.

P. Lønning, S. Knappskog, J. Lillehaug, 2013, Biochimica et biophysica acta.

Polymorphisms in the TP53-MDM2-MDM4-axis in patients with Rheumatoid Arthritis.

P. Lønning, B. Lie, L. Vatten, 2021, Gene.

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer

P. Lønning, L. Vatten, P. Romundstad, 2016, Scientific Reports.

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

P. Lønning, L. Vatten, P. Romundstad, 2015, International journal of cancer.

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

P. Lønning, J. Forbes, R. Coombes, 2007, The Lancet.

Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers

P. Lønning, S. Knappskog, J. Geisler, 2017, The Journal of Steroid Biochemistry and Molecular Biology.

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.

P. Lønning, M. Dowsett, J. Geisler, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

2. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer

P. Lønning, M. Dowsett, S. Lundgren, 1995 .

Aromatase inhibitors—Socio-economical issues

P. Lønning, J. Geisler, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Exemestane for breast cancer prevention: a feasible strategy?

P. Lønning, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Is There a Growing Role for Endocrine Therapy in the Treatment of Breast Cancer?

P. Lønning, 2000, Drugs.

Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.

P. Lønning, J. Klijn, L. Ottestad, 2005, European journal of cancer.

Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients.

P. Lønning, K. Hall, A. Aakvaag, 1992, Cancer research.

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

P. Lønning, B. Erikstein, J. Geisler, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aromatase Inhibition: Translation into a Successful Therapeutic Approach

P. Lønning, J. Geisler, 2005, Clinical Cancer Research.

The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status

P. Lønning, I. Endo, Yuhree Kim, 2019, Annals of surgery.

Alterations in plasma IGF-I caused by hormone manipulation; of relevance to the mechanism of action and acquired resistance to endocrine treatment in breast cancer?

P. Lønning, J. Holly, K. Hall, 1995 .

Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges.

P. Lønning, J. Geisler, 2001, Clinical breast cancer.

Prototype precision oncology learning ecosystem: Norwegian precision cancer medicine implementation initiative.

P. Lønning, E. Hovig, B. Gjertsen, 2022, Journal of Clinical Oncology.

A national precision cancer medicine implementation initiative for Norway

Tonje G. Lien, P. Lønning, R. Lothe, 2022, Nature Medicine.

Insulin-like growth factors in breast cancer.

P. Lønning, S. Helle, P. Lønning, 1996, Acta oncologica.

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

P. Lønning, J. Olsen, J. Norum, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication.

P. Lønning, R. Bjerkvig, A. Jul-Larsen, 2004, Experimental cell research.

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma

P. Lønning, V. Kristensen, J. Geisler, 2013, PloS one.

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma

P. Lønning, S. Knappskog, G. Jönsson, 2013, Clinical & Experimental Metastasis.

Evolution of endocrine adjuvant therapy for early breast cancer

P. Lønning, 2010, Expert opinion on investigational drugs.

Tailored targeted therapy for all: a realistic and worthwhile objective?

P. Lønning, 2009, Breast Cancer Research.

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

P. Lønning, 2012, Therapeutic advances in medical oncology.

Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation

P. Lønning, M. Dowsett, S. Knappskog, 2011, Clinical Cancer Research.

Recent data on intratumor estrogens in breast cancer

P. Lønning, M. Dowsett, S. Knappskog, 2011, Steroids.

Cross-resistance to different aromatase inhibitors in breast cancer treatment.

P. Lønning, 1999, Endocrine-related cancer.

Experience with Exemestane in the Treatment of Early and Advanced Breast Cancer

P. Lønning, J. Geisler, 2008 .

Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations

P. Lønning, P. Møller, H. Myhre, 2007, Acta oncologica.

Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.

P. Lønning, J. Geisler, J. Holly, 1998, British Journal of Cancer.

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.

P. Lønning, K. Wester, P. Ueland, 1991, British Journal of Cancer.

Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer

T. Aas, P. Lønning, L. Akslen, 1997, International journal of cancer.

A novel type of deletion in the CDKN2A gene identified in a melanoma‐prone family

P. Lønning, S. Knappskog, J. Geisler, 2006, Genes, chromosomes & cancer.

Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance.

P. Lønning, 2004, Trends in molecular medicine.

Lapatinib in early breast cancer--questions to be resolved.

P. Lønning, 2013, The Lancet. Oncology.

Are current development programs realising the full potential of new agents?

P. Lønning, 2010, Breast Cancer Research.

Alterations of the retinoblastoma gene in metastatic breast cancer

P. Lønning, S. Knappskog, J. Lillehaug, 2011, Clinical & Experimental Metastasis.

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers

S. Geisler, P. Lønning, A. Børresen-Dale, 2010, Molecular Cancer.

Aromatase inhibitors as adjuvant treatment of breast cancer.

P. Lønning, J. Geisler, 2006, Critical reviews in oncology/hematology.

BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?

P. Lønning, S. Knappskog, 2018, Clinical Epigenetics.

C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer

P. Lønning, S. Knappskog, A. Molven, 2022, Nature Communications.

DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

T. Aas, S. Geisler, P. Lønning, 2010, Molecular Cancer.

Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival

Joe W. Gray, Ajay N. Jain, Koei Chin, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.

P. Lønning, S. Knappskog, J. Geisler, 2010, The Journal of investigative dermatology.

Screening breast cancer patients for Norwegian ATM mutations

P. Lønning, A. Børresen-Dale, B. Erikstein, 2000, British Journal of Cancer.

Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer

M. Beckmann, P. Lønning, K. Blackwell, 2010, Expert review of anticancer therapy.

Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome.

T. Aas, S. Geisler, P. Lønning, 1996, Acta oncologica.

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

P. Lønning, S. Lundgren, S. Knappskog, 2012, Breast Cancer Research.

Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension

S. Geisler, P. Lønning, L. Akslen, 2012, PloS one.

Plasma levels of estradiol, estrone, estrone sulfate and sex hormone binding globulin in patients receiving rifampicin.

P. Lønning, A. Gulsvik, P. Bakke, 1989, Journal of steroid biochemistry.

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

P. Lønning, 2020, Trends in cancer.

Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings.

P. Lønning, S. Lundgren, A. Aakvaag, 1990, Journal of steroid biochemistry.

The relation between cell proliferation and adenylate cyclase activity in grafts of 3-methylcholanthrene induced mouse uterine cervical tumors

P. Lønning, J. Forsberg, S. Kvinnsland, 1982, Experientia.

Determination of warfarin in human plasma by high performance liquid chromatography and photodiode array detector.

P. Lønning, P. Ueland, G. Kvalheim, 1985, Therapeutic drug monitoring.

Interaction between p53 Staining and High-Dose Chemotherapy in Breast Cancer

P. Lønning, A. Børresen-Dale, 2006, Clinical Cancer Research.

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

Sigrun M. Hjelle, P. Lønning, S. Knappskog, 2012, Oncogene.

MDM2 SNP309 and risk of cervical cancer

P. Lønning, S. Knappskog, 2014, Tumor Biology.

Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.

P. Lønning, S. Lundgren, J. Geisler, 1998, The Journal of clinical endocrinology and metabolism.

A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide

S. Geisler, P. Lønning, A. Børresen-Dale, 2009, Clinical Cancer Research.

Genetic variants of CYP19 (aromatase) and breast cancer risk

P. Lønning, A. Børresen-Dale, N. Harada, 2000, Breast Cancer Research.

rs2735383, located at a microRNA binding site in the 3’UTR of NBS1, is not associated with breast cancer risk

S. Cross, M. Beckmann, P. Fasching, 2016, Scientific Reports.

Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications.

Vessela N Kristensen, Therese Sørlie, Anita Langerød, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized placebo-controlled study

P. Lønning, L. Ottestad, J. Geisler, 2004 .

Systemic Therapy in Breast Cancer

P. Lønning, J. Corry, 1994, PharmacoEconomics.

Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer

A. Frigessi, I. Glad, T. Sørlie, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy.

P. Lønning, Y. Kienast, F. Meric-Bernstam, 2016, JCI insight.

Effects of treatment with megestrol acetate on the insulin-like growth factor system: time and dose dependency.

S. Geisler, P. Lønning, S. Lundgren, 1999, European journal of cancer.

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer

P. Lønning, S. Knappskog, G. Mellgren, 2015, PloS one.

The optimal cut‐off values for tumor size, number of lesions, and CEA levels in patients with surgically treated colorectal cancer liver metastases: An international, multi‐institutional study

P. Lønning, I. Endo, P. Kornprat, 2021, Journal of surgical oncology.

Influence of treatment with tamoxifen and change in tumor burden on the IGF‐system in breast cancer patients

P. Lønning, M. Tally, J. Holly, 1996, International journal of cancer.

Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour

P. Lønning, S. Knappskog, K. Gravdal, 2012, European journal of endocrinology.

Neoadjuvant olaparib monotherapy in primary triple negative breast cancer

T. Aas, P. Lønning, S. Lundgren, 2019, Annals of Oncology.

Endocrine effects of aromatase inhibitors.

P. Lønning, M. Dowsett, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer

P. Lønning, P. Ueland, S. Kvinnsland, 2004, Cancer Chemotherapy and Pharmacology.

[Treatment of advanced breast cancer with aminoglutethimide].

P. Lønning, S. Kvinnsland, 1984, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Relations between sex hormones, sex hormone binding globulin, insulin‐like growth factor‐I and insulin‐like growth factor binding protein‐I in post‐menopausal breast cancer patients

P. Lønning, H. Adlercreutz, G. Anker, 1995, Clinical endocrinology.

Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer

P. Lønning, 2006 .

Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.

P. Lønning, B. Walter, R. Mccague, 1995, Drug metabolism and disposition: the biological fate of chemicals.

Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer.

P. Lønning, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.

T. Aas, S. Geisler, P. Lønning, 2005, Oncology reports.

ramr: an R/Bioconductor package for detection of rare aberrantly methylated regions

Stian Knappskog, Oleksii Nikolaienko, Per Eystein Lønning, 2021, Bioinform..

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

P. Lønning, T. Bathen, B. Sitter, 2012, BMC Cancer.

Aminoglutethimide and warfarin

P. Lønning, S. Kvinnsland, G. Jahren, 2004, Cancer Chemotherapy and Pharmacology.

Determination of Aminoglutethimide and N‐Acetylaminoglutethimide in Human Plasma by Reversed‐Phase Liquid Chromatography

P. Lønning, P. Ueland, S. Kvinnsland, 1984, Therapeutic drug monitoring.

Treatment of breast carcinoma with aminoglutethimide.

P. Lønning, O. Dahl, S. Kvinnsland, 1984, Acta radiologica. Oncology.

Aminoglutethimide as an inducer of microsomal enzymes. Part 1: Pharmacological aspects.

P. Lønning, P. Ueland, S. Kvinssland, 1986, Breast cancer research and treatment.

Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients

P. Lønning, H. Adlercreutz, T. Fotsis, 1995, The Journal of Steroid Biochemistry and Molecular Biology.

Preface

P. Lønning, M. Dowsett, 2011, Steroids.

Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients.

P. Lønning, J. Cameron, T. Pawlik, 2019, Annals of surgery.

BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based tr

P. Lønning, T. Decker, A. Leo, 2015 .

Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma

P. Lønning, S. Lundgren, E. Diamandis, 1999, Cancer.

Influence of treatment with onapristone on the IGF-system in breast cancer patients

P. Lønning, W. Jonat, J. Holly, 1998, The Journal of Steroid Biochemistry and Molecular Biology.

Aromatase inhibitors—Socioeconomical issues

P. Lønning, J. Geisler, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--II. A differential effect of megestrol acetate and medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin.

P. Lønning, S. Lundgren, 1990, Journal of steroid biochemistry.

Anastrozole--a new generation in aromatase inhibition: clinical pharmacology.

P. Lønning, M. Dowsett, 1997, Oncology.

Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer.

P. Lønning, J. Geisler, S. Gundersen, 1995, The Journal of endocrinology.

Strength and weakness of phase I to IV trials, with an emphasis on translational aspects

P. Lønning, 2008, Breast Cancer Research.

Comments on paper: “Quantitative determination of estrone by liquid chromatography–tandem mass spectrometry in subcutaneous adipose tissue from the breast in postmenopausal women” by Vihma et al.

P. Lønning, 2016, The Journal of Steroid Biochemistry and Molecular Biology.

Effects of SNP variants in the 17β-HSD2 and 17β-HSD7 genes and 17β-HSD7 copy number on gene transcript and estradiol levels in breast cancer tissue

P. Lønning, S. Knappskog, A. H. Straume, 2014, The Journal of Steroid Biochemistry and Molecular Biology.

Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women

P. Lønning, S. Knappskog, A. H. Straume, 2012, The Journal of Steroid Biochemistry and Molecular Biology.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES

P. Lønning, M. Cheang, V. Speirs, 2017, Breast Cancer Research and Treatment.

The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis

P. Lønning, T. Pawlik, elliot k fishman, 2018, Journal of surgical oncology.

The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer

P. Lønning, A. Børresen-Dale, I. Gram, 2006, Clinical Cancer Research.

Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?

P. Lønning, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer

T. Aas, S. Geisler, P. Lønning, 2001, British Journal of Cancer.

BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?

P. Lønning, S. Knappskog, 2018, Clinical Epigenetics.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer.

P. Lønning, 2017, JAMA oncology.

Experience with exemestane in the treatment of early and advanced breast cancer.

P. Lønning, J. Geisler, 2008, Expert opinion on drug metabolism & toxicology.

Aromatase inhibition versus placebo.

P. Lønning, 2008, Clinical breast cancer.

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells

P. Lønning, S. Knappskog, B. Mannsăker, 2017, BMC Cell Biology.

Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.

P. Lønning, J. Baselga, H. Iwata, 2013 .

Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients

P. Lønning, A. Svardal, R. Berge, 1998, Cancer Chemotherapy and Pharmacology.

Changes in bone metabolism after 2 years' treatment with exemestane (E) in postmenopausal women with early breast cancer (EBC) at low risk: Follow-up (FU) results of a randomized placebo-controlled study

P. Lønning, L. Ottestad, J. Geisler, 2005 .

Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized placebo-controlled study.

P. Lønning, L. Ottestad, J. Geisler, 2004, Journal of Clinical Oncology.

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk

P. Lønning, L. Vatten, P. Romundstad, 2017, BMC Cancer.

Determination of Droloxifene and Two Metabolites in Serum by High‐Pressure Liquid Chromatography

P. Lønning, P. Ueland, E. Lien, 1995, Therapeutic drug monitoring.

Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

P. Lønning, P. Ueland, E. Lien, 2004, Journal of the National Cancer Institute.

Aminoglutethimide as an inducer of microsomal enzymes. Part 2: Endocrine aspects.

T. Thorsen, P. Lønning, D. Ekse, 1986, Breast cancer research and treatment.

Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen.

P. Lønning, G. Anker, P. Ueland, 1999, Cancer letters.

Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer

P. Lønning, B. Krishnamachary, I. Gribbestad, 2012, NMR in biomedicine.

epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data

P. Lønning, S. Knappskog, O. Nikolaienko, 2022, bioRxiv.

Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development

S. Geisler, P. Lønning, S. Knappskog, 2023, Genome Medicine.

Treatment of breast cancer with aromatase inhibitors

P. Lønning, D. Johannessen, 1991 .

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

P. Lønning, H. Ditzel, T. Tan, 2019, Cancer & metabolism.

IGF-1 and breast cancer.

P. Lønning, S. Helle, 2004, Novartis Foundation symposium.

Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients.

S. Geisler, P. Lønning, J. Geisler, 1998, Clinical Cancer Research.

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma

P. Lønning, S. Knappskog, G. Jönsson, 2013, Clinical & Experimental Metastasis.

MDM2 SNP309 and risk of endometrial cancer.

P. Lønning, S. Knappskog, 2013, Polish journal of pathology : official journal of the Polish Society of Pathologists.

Mechanisms of action of endocrine treatment in breast cancer.

P. Lønning, E. Lien, E. Lønning, 1995, Critical reviews in oncology/hematology.

Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.

P. Lønning, M. Dowsett, L. Ottestad, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

X chromosome inactivation in cervical cancer patients.

P. Lønning, A. Børresen-Dale, G. Kristensen, 2003, Cancer genetics and cytogenetics.

A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

P. Lønning, L. Fallowfield, L. Gibson, 2004 .

Demystifying BRAF Mutation Status in Colorectal Liver Metastases

P. Lønning, T. Pawlik, P. Kornprat, 2022, Annals of Surgery.

Evaluation of MetriGenix custom 4D™ arrays applied for detection of breast cancer subtypes

T. Sørlie, H. Johnsen, P. Lønning, 2006, BMC Cancer.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES

P. Lønning, M. Cheang, V. Speirs, 2017, Breast Cancer Research and Treatment.

Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.

G. Colditz, P. Lønning, C. Osborne, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation.

P. Lønning, H. Immervoll, R. Bjerkvig, 2009, Cancer research.

Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome

M. Ringnér, P. Lønning, Å. Borg, 2010, Clinical Cancer Research.

Lapatinib in early breast cancer--questions to be resolved.

P. Lønning, 2013, The Lancet. Oncology.

Systemic therapy in breast cancer: efficacy and cost utility.

P. Lønning, J. Corry, 1994, PharmacoEconomics (Auckland).

Patterns of genomic evolution in advanced melanoma

P. Lønning, E. Hovig, O. Myklebost, 2018, Nature Communications.

Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter.

P. Lønning, S. Knappskog, A. Molven, 2010, Cancer research.

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.

P. Lønning, M. Dowsett, N. Davidson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients

P. Lønning, J. Geisler, G. Mellgren, 2021, The Journal of clinical endocrinology and metabolism.

The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.

P. Lønning, A. Børresen-Dale, David Evans, 2011, Cancer cell.

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

T. Aas, P. Lønning, S. Knappskog, 2023, JCO precision oncology.